.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BD07_CasirivimabAndImdevimab.CasirivimabAndImdevimab .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BD07_CasirivimabAndImdevimab.CasirivimabAndImdevimab| name: | CasirivimabAndImdevimab |
| ATC code: | J06BD07 | route: | intravenous |
| n-compartments | 2 |
Casirivimab and imdevimab are recombinant human monoclonal antibodies that bind to non-overlapping epitopes of the spike protein of SARS-CoV-2, thereby blocking viral entry into human cells. They are used together as a combination therapy for the treatment and post-exposure prophylaxis of COVID-19. The combination received emergency use authorization during the COVID-19 pandemic.
Pharmacokinetic parameters estimated for healthy adults and COVID-19 patients; the following parameters are representative values from available regulatory and pharmacology reviews.